1104 peptide 1104 - Revolo1104 peptide The Revolutionary Potential of the 1104 Peptide in Immune Homeostasis and Allergic Disease Treatment

Revolo biotherapeutics The 1104 peptide is emerging as a groundbreaking therapeutic agent, poised to redefine the treatment landscape for a range of allergic diseases.Today we shared new data that elucidates the upstream mechanism of action for our first-in-classpeptide. Uniquely, '1104affects both the ... Developed by Revolo Biotherapeutics, this first-in-class peptide is not merely another treatment but a novel approach to restoring immune balance2025年8月6日—Its two drug candidates, '1104and '1805, apeptideand a protein respectively, restore immune homeostasis to prevent the chronic pro .... Its unique mechanism of action targets the root causes of inflammation, offering a promising alternative to existing therapies that often focus on downstream effectsProduct Development Landscape | '1104. This article delves into the science behind the 1104 peptide, its development, clinical progress, and the potential it holds for patients suffering from conditions like eosinophilic esophagitis (EoE) and atopic dermatitis (AD).

Understanding the Mechanism: Resetting the Immune System

Unlike many current treatments that manage symptoms by suppressing the immune response, the 1104 peptide operates upstream in the inflammatory cascade. It acts as an immune-resetting peptide, uniquely influencing both the regulatory and effector arms of the immune system. This comprehensive approach aims to restore immune homeostasis, a state of equilibrium where the immune system can effectively defend against pathogens without overreacting to harmless substances.

The 1104 peptide has demonstrated its ability to bind to antigen-presenting cells, modulating their activity and thereby preventing the chronic pro-inflammatory responses characteristic of allergic diseases. New data has elucidated the upstream mechanism of action for this first-in-class peptide, highlighting its distinct role in the immune regulatory process. This mechanism is described as targeting the root cause of allergic disease, a significant advancement in therapeutic strategyIRL201104 / Revolo Biotherap.

Clinical Development and Regulatory Milestones

The development of the 1104 peptide has been marked by significant progress and positive clinical outcomesMechanisms of Peptide Immunotherapy in Allergic Airways .... Revolo Biotherapeutics has advanced the 1104 peptide through multiple clinical trials, including Phase 2a studiesPeptide Shows Promise as an Allergen-Agnostic Treatment .... Notably, the US Food and Drug Administration (FDA) has recognized the potential of this novel therapeutic by granting Orphan Drug Designation (ODD) to '1104 for the treatment of eosinophilic esophagitis (EoE)2021年4月19日—Its two drug candidates, '1805 and '1104, a protein and apeptiderespectively, reset the immune system by preventing the chronic pro .... This designation is crucial as it provides incentives for the development of drugs for rare diseases and underscores the unmet medical need in this area.

Positive topline data from a Phase 2a clinical trial for patients with eosinophilic esophagitis has been reported, further solidifying the peptide's promise. The company has also completed enrollment in another Phase 2a clinical trial, indicating a robust development pipeline. Furthermore, the FDA has approved the Investigational New Drug (IND) application for '1104 for eosinophilic esophagitis, paving the way for further clinical investigation2024年6月13日—'1104is apeptidederived from a natural immune-regulatory protein and has recently completed a Phase 2a clinical trial for patients with ....

Targeting Eosinophilic Esophagitis and Beyond

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disease characterized by the accumulation of eosinophils in the esophagus, leading to inflammation and damage. The 1104 peptide is specifically intended for the treatment of allergic diseases such as EoE, aiming to halt the characteristic inflammation associated with the condition.

Beyond EoE, the 1104 peptide is also being investigated for its potential in treating other type 2 inflammatory allergic diseases, including atopic dermatitis (AD). Preclinical data has shown that IRL201104 (1104), a novel immunomodulatory peptide, significantly reduced skin thickness and pathology in a chronic allergen-driven murine model of AD. This suggests that the 1104 peptide may offer an allergen-agnostic treatment approach, benefiting a wide range of patients with allergic conditions.

Safety and Dosing

The safety profile of the 1104 peptide has been evaluated in clinical trials.Revolo's '1104 is a first-in-class peptidethat is involved in restoring immune homeostasis, impacting both the regulatory and effector arms of the immune ... In a study exploring dose escalation, healthy volunteers tolerated doses of 16 mg, 32 mg, and 64 mg, with the 1104 peptide aiming for long-term disease remission without immunity suppression. This indicates a favorable safety margin, a critical factor for any therapeutic intervention.

Future Directions and the Broader Impact

The development of the 1104 peptide represents a significant leap forward in the understanding and treatment of allergic diseases.IRL201104 / Revolo Biotherap Its ability to reset the immune system, rather than just managing symptoms, offers the potential for more durable and effective outcomes. The exploration of an orally administered formulation of '1104 further enhances its potential accessibility and patient convenience.

While the focus has been on eosinophilic esophagitis and atopic dermatitis, the underlying principle of immune resetting could have broader implications for other immune-mediated conditions. The ongoing research into the 1104 peptide and its upstream mechanisms of action by Revolo Biotherapeutics is crucial for unlocking its full therapeutic potential.

It is important to distinguish this therapeutic peptide from other entities that may share similar identifiers2021年4月19日—Its two drug candidates, '1805 and '1104, a protein and apeptiderespectively, reset the immune system by preventing the chronic pro .... For instance, PEP-1104 is a synthetic peptide corresponding to 14 amino acids of human SCUBE1 and can be used as a blocking peptide with a polyclonal antibody.Revolo advances plans to tackle eosinophilic esophagitis ... Furthermore, research into naturally processed peptides has identified variations such as self peptides displayed on 1104 molecules, which are distinct from the therapeutic 1104 peptide2024年10月21日—Its two drug candidates, '1104and '1805, apeptideand a protein respectively, restore immune homeostasis to prevent the chronic pro ....

The journey of the 1104 peptide from preclinical research to advanced clinical trials and regulatory recognition highlights the power of innovative science in addressing complex medical challenges. As development continues, this first-in-class immune-resetting peptide holds the promise of transforming lives for individuals grappling with the burden of allergic diseases.2024年10月21日—Its two drug candidates, '1104and '1805, apeptideand a protein respectively, restore immune homeostasis to prevent the chronic pro ...